Loading clinical trials...

Radiation to Treat Joint Damage Caused by Cancer Immunotherapy | Clinical Trials | Clareo Health

NOT_YET_RECRUITINGPHASE1

Radiation to Treat Joint Damage Caused by Cancer Immunotherapy

Use of Low-Dose RADiotherapy in the Management of Immune Checkpoint- Inhibitor-ArThropathy as an Immune-Related Adverse Event (RADIATE)

NCT07478679•University of Chicago

View on ClinicalTrials.gov

Summary

This study will prospectively investigate the feasibility and safety of administering LDRT in patients with immunotherapy-induced inflammatory arthritis.

Eligibility

Age

40 - No limit years

Sex

ALL

Healthy Volunteers

Inclusion Criteria

•Patients must have histologically confirmed malignancy that is metastatic or unresectable and for which they are receiving single agent or combination immunotherapy or within the last 6 months.
•Rheumatologist-established diagnosis of new onset CTCAE grade 2-3 immunotherapy-induced inflammatory arthritis or activated osteoarthritis, involving one or more joints (up to 3) including but not limited to hands, shoulders, elbows, hips, knees and ankles.
•Age ≥ 40 years.
•ECOG performance status ≤2 (Karnofsky ≥60%).
•Patients with ability and willingness to sign consent.

Exclusion Criteria

•Contraindications to radiation treatment, such as pregnancy, breast-feeding women and active collagen-vascular disease.
•Women of child-bearing potential who have positive urine or serum pregnancy test or refuse to do pregnancy test unless last menstrual cycle was \>1 year prior to consent and/or clear documentation states that the patient is peri- or post-menopausal or there was recent supporting objective evidence of 'no pregnancy' status (e.g. blood or imaging) within 30 days prior to initiation of study treatment.
•Have not received systemic steroids within the last 3 months for the treatment of immune related adverse events.
•History of prior autoimmune conditions, or concurrent immune related adverse events requiring systemic immunosuppressants.
•Estimated life expectancy less than 3 months as assessed by investigators.
•Any condition at the discretion of investigator that will preclude participation in the study.
•History of secondary malignancy as assessed by investigators.
•History of radiation to affected joints as assessed by investigators.

Locations (1)

The University of Chicago Medicine Comprehensive Cancer Center

Chicago, Illinois, United States

Key Dates

Start Date

August 26, 2026

Primary Completion Date

September 17, 2028

Completion Date

September 17, 2028

Last Updated

March 17, 2026

Enrollment

ESTIMATED participants

Conditions

ArthritisArthropathy

Interventions

Low dose radiation therapy

RADIATION

Contacts

Clinical Trials Intake

CONTACT

855-702-8222 cancerclinicaltrials@bsd.uchicago.edu

Clinical Cohort Construction and Therapeutic Effect Evaluation of Integrated Traditional Chinese and Western Medicine in the Treatment of Rheumatoid Arthritis

NCT07484243

Rheumatoid Arthritis (RA)Rheumatoid Arthritis-Associated Interstitial Lung Disease+1 more

View study

RECRUITINGPHASE3

A Study of Orforglipron (LY3502970) in Participants With Obesity or Overweight and Osteoarthritis (OA) of the Knee

NCT07153471

Osteoarthritis

View study

Data Source & Attribution

This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.

ClinicalTrials.gov last update: March 17, 2026Data synced to Clareo: March 29, 2026

Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.

Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.

View ClinicalTrials.gov Terms and Conditions

Radiation to Treat Joint Damage Caused by Cancer Immunotherapy

Inclusion Criteria

Exclusion Criteria

Clinical Cohort Construction and Therapeutic Effect Evaluation of Integrated Traditional Chinese and Western Medicine in the Treatment of Rheumatoid Arthritis

A Study of Orforglipron (LY3502970) in Participants With Obesity or Overweight and Osteoarthritis (OA) of the Knee

A Study of Picankibart in Patients With Active Psoriatic Arthritis

Natural History and Development of Spondyloarthritis

A Study to Evaluate the Safety and Activity of SAR448501/DR-0201 in Patients With Autoimmune Rheumatic Diseases

Targeted Remotely-delivered Anti-inflammatory Interventions With Exercise for Rheumatoid Arthritis